Skip to main content
Profile picture for Adela Castro, MD

Adela Castro, MD

Dr. Castro is an assistant professor of Medicine and Rheumatology at the University of Tennessee Health Science Center in Memphis. With a strong background in both clinical practice and academic medicine, her research interests focus on topics such as psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.  Dr. Castro is also actively involved in medical education as well as volunteer activities in professional societies, including the American College of Rheumatology and the Association of Women in Rheumatology. 

Articles By Adela Castro, MD

pain

Not All Pain in Rheumatic Disease is Inflammatory

The term nociplastic pain refers to pain arising from altered central nervous system processing, without evidence of tissue or nerve damage.

Read Article
light bulb idea

Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA

14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA pathogenesis (1).

Read Article
SI joint on green background

Reading the Sacroiliac Joint Early: What MRI Reveals in axSpA

Axial spondyloarthritis is notorious for being diagnosed late. Imaging is one of the best tools for catching it sooner, and the 2025 ASAS-SPARTAN revised classification criteria reflect that: the most heavily weighted variable is “MRI indicative of axSpA in the sacroiliac joints (SIJ).” Three new abstracts from the SPACE and SPARTAN CLASSIC cohorts show what that finding means in practice.

Read Article
takayasu.jpg

Diagnosing and Managing GCA and Takayasu’s Arteritis

Giant-cell arteritis and Takayasu’s arteritis are both large-vessel vasculitides, but each brings its own diagnostic and management challenges. Many of the difficulties overlap because they are rare, heterogeneous, and lack perfect diagnostic tests or specific biomarkers.

Read Article
osteoporosis.OP_.Drugs_.jpg

A Modern Approach to Osteoporosis Management

Currently, fewer than half of patients diagnosed with osteoporosis receive appropriate pharmacologic therapy. This treatment gap reflects several challenges in osteoporosis management, including limited disease awareness, barriers to medication access, clinician discomfort with therapy selection, and uncertainty regarding the optimal timing of treatment initiation.

Read Article
back, LBP, spine, AS

Imaging in Axial Spondyloarthritis

The diagnosis of axial spondyloarthritis (axSpA) is clinical, however, there are still unmet needs, particularly in the diagnosis of early disease and evaluation of disease activity and progression. As imaging technology continues to evolve, its role in axSpA management is expected to expand, offering more precise, individualized care. Here are two studies presented at EULAR 2025.

Read Article
IL17

Expanding the IL-17 Therapeutic Landscape

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

Read Article
Kavanaugh RNL 25

Combination biologics in PsA: are we there yet?

Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.

Read Article
AI

Will AI put me out of a job?

The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect".

Read Article
men and women

ICYMI: Sex related differences in PsA

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).

Read Article
×